Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shexiang Baoxin Pill for Coronary Microvascular Disease (TCM Syndrome-Based Evaluation)
ChiCTR2600116679Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Jan 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Shexiang Baoxin Pill in Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Beijing University of Chinese Medicine. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Shexiang Baoxin Pill
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR2600116679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116679.